September 27th 2023
Two posters presented at the European Respiratory Society International Congress found use of Dupixent improved lung function by 12 weeks with sustained responses.
September 25th 2023
Majority of Patients With CRSwNP Have Type 2 Inflammatory Signatures
August 10th 2023A post hoc analysis of two phase 3 trials identified that as many as 95% of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) had type 2 inflammatory signatures depending on the definition of inflammation used.
Read More
Differences in Patient Characteristics, Treatment of EoE by Allergists and Gastroenterologists
December 12th 2022Most (91%) of the patients were seen by gastroenterologists. Those seen by allergists were more likely to have comorbid atopic conditions, such as asthma, allergic rhinitis and atopic dermatitis.
Read More
Long-term Use of Dupixent Effective for Patients With Asthma Regardless of CRSwNP Status
December 9th 2022Patients with severe asthma with or without coexisting chronic rhinosinusitis and nasal polyps (CRSwNP) experienced continued improvements in exacerbations and lung function in an extension study.
Read More
Variation by Age of EoE Symptoms May Contribute to Delayed Diagnosis for Some Patients
December 6th 2022Patients with eosinophilic esophagitis experience a range of symptoms that can vary by age, which may contribute to younger patients experiencing a delay in diagnosis, according to a poster presented at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
Read More
Real-World Study Shows Dupixent Improves AD Symptoms in Children Under 12 Years
October 5th 2022A real-world study of children with moderate-to-severe atopic dermatitis (AD) in China found Dupixent can reduce symptoms and improve pruritus. Traditional therapies had little effect, according to the researchers.
Read More
Extension Trial Shows Positive Results for Dupixent
September 7th 2022Results reported at a meeting of the European Respiratory Society this week show a low rate of severe asthma attacks and sustained improvement in lung function among the children who participated in the yearlong add-on study.
Read More
Patients With Moderate-to-Severe Atopic Dermatitis Experience Impaired QOL, Feel Disease Burden
September 7th 2022A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.
Read More
Management of EoE May Need to Be Rethought to Reduce Treatment Burden, Impact on Quality of Life
September 2nd 2022Therapeutic goals of reducing eosinophil counts below a certain level in eosinophilic esophagitis (EoE) has a marginal benefit for the impact on quality of life and treatment burden.
Read More
There Remains an Unmet Need for EoE Treatments That Provide Effective, Long-term Disease Control
May 5th 2022Patients with eosinophilic esophagitis (EoE) are faced with delayed diagnosis, burdens related to symptoms, quality of life and cost, but lack targeted systemic therapies to improve long-term disease control.
Read More
Researchers Compare Correlation of Two PROMs With Type 2 Inflammatory Mediators
May 1st 2022In patients with chronic rhinosinusitis with nasal polyps, the 12-item Patient Reported Outcomes in Chronic Rhinosinusitis had a stronger correlation with type 2 inflammatory biomarkers than a more widely used measure.
Read More
Identifying Disparities in Treatment and Quality of Care Team Relationships for Patients With Asthma
March 15th 2022Research presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting found minority patients with asthma perceived lower quality interactions with their care team, but did not find significant differences in the prescription of biologic medications across racial/ethnic groups.
Read More